Research
Hormonal
GLP-1 receptor agonists (GLP-1 RAs) can lead to modest yet statistically significant reductions in systolic blood pressure (SBP).
GLP-1 RAs may be considered as adjunctive therapies for managing hypertension.
StrongSupportsmedium confidence
Clinical trials demonstrate modest yet statistically significant reductions in systolic blood pressure (SBP).
Why this rating
Based on clinical trials mentioned in the abstract.
Source
Impact of glucagon-like peptide-1 receptor agonists on hypertension management: a narrative review
Diana De Oliveira-Gomes et al. · Current Opinion in Cardiology · 2025
DOI 10.1097/hco.0000000000001225
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →